Ideas:
“
Targeting Hyper-inflammation in COVID-19 with Bromodomain (BRD-2/4) inhibitors: Acute respiratory distress accompanied by hyper-inflammation is the leading cause of deaths in COVID-19. In stage I (mild infection) the anti-inflammatory therapies can be detrimental. However, in stage III subset of COVID-19 patients, with severe systemic hyper inflammation, the use of immunomodulatory agents may be useful approach. SARS-CoV-2 human protein-protein interaction map revealed bromodomain (BRD) protein as an important drug target. BRD’s serves as readers of lysine acetylation on histones, a key event in transcriptional activation for the immune response. The transmembrane protein E of SARS-CoV-2 shares similarity to N-terminus of histone 2A and disrupts the interaction between BRD-2 and histone, thus inducing transcription of proteins beneficial to the virus. This virus-host protein interaction can be interrupted by using BRD-2/4 inhibitors.
”
Feedback